Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Work In Process (2023 - 2025)

Verrica Pharmaceuticals has reported Work In Process over the past 3 years, most recently at $523000.0 for Q2 2025.

  • Quarterly results put Work In Process at $523000.0 for Q2 2025, down 23.43% from a year ago — trailing twelve months through Jun 2025 was $523000.0 (down 23.43% YoY), and the annual figure for FY2024 was $664000.0, up 36.34%.
  • Work In Process for Q2 2025 was $523000.0 at Verrica Pharmaceuticals, up from $179000.0 in the prior quarter.
  • Over the last five years, Work In Process for VRCA hit a ceiling of $750000.0 in Q3 2024 and a floor of $179000.0 in Q1 2025.
  • Median Work In Process over the past 3 years was $664000.0 (2024), compared with a mean of $564857.1.
  • Biggest five-year swings in Work In Process: surged 36.34% in 2024 and later crashed 73.2% in 2025.
  • Verrica Pharmaceuticals' Work In Process stood at $487000.0 in 2023, then surged by 36.34% to $664000.0 in 2024, then decreased by 21.23% to $523000.0 in 2025.
  • The last three reported values for Work In Process were $523000.0 (Q2 2025), $179000.0 (Q1 2025), and $664000.0 (Q4 2024) per Business Quant data.